Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- Resource Type
- Article
- Source
- In
The Lancet Oncology September 2016 17(9):1272-1282 - Subject
Primary Research Articles - Language
- ISSN
- 1470-2045